Amgen, Inc. (AMGN)
467.06
-1.05
(-0.22%)
USD |
NASDAQ |
Nov 12, 16:00
469.13
+2.07
(+0.44%)
After-Hours: 04:13
Amgen Price to Book Value : 17.60 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 17.60 |
| November 11, 2026 | 17.64 |
| November 10, 2026 | 17.53 |
| November 09, 2026 | 17.53 |
| November 06, 2026 | 17.35 |
| November 05, 2026 | 17.35 |
| November 04, 2026 | 18.03 |
| November 03, 2026 | 17.38 |
| November 02, 2026 | 17.54 |
| October 30, 2026 | 17.56 |
| October 29, 2026 | 17.36 |
| October 28, 2026 | 17.03 |
| October 27, 2026 | 16.88 |
| October 26, 2026 | 16.76 |
| October 23, 2026 | 16.55 |
| October 22, 2026 | 16.86 |
| October 21, 2026 | 16.52 |
| October 20, 2026 | 16.54 |
| October 19, 2026 | 16.02 |
| October 16, 2026 | 16.30 |
| October 15, 2026 | 16.36 |
| October 14, 2026 | 16.06 |
| October 13, 2026 | 15.56 |
| October 12, 2026 | 15.74 |
| October 09, 2026 | 15.64 |
| Date | Value |
|---|---|
| October 08, 2026 | 15.36 |
| October 07, 2026 | 15.57 |
| October 06, 2026 | 15.17 |
| October 05, 2026 | 15.19 |
| October 02, 2026 | 15.19 |
| October 01, 2026 | 15.35 |
| September 30, 2026 | 15.89 |
| September 29, 2026 | 19.59 |
| September 28, 2026 | 19.34 |
| September 25, 2026 | 19.18 |
| September 24, 2026 | 18.78 |
| September 23, 2026 | 18.78 |
| September 22, 2026 | 18.97 |
| September 21, 2026 | 18.18 |
| September 18, 2026 | 17.84 |
| September 17, 2026 | 17.57 |
| September 16, 2026 | 17.41 |
| September 15, 2026 | 17.37 |
| September 14, 2026 | 17.65 |
| September 11, 2026 | 17.45 |
| September 10, 2026 | 17.69 |
| September 09, 2026 | 18.10 |
| September 08, 2026 | 18.19 |
| September 04, 2026 | 20.22 |
| September 03, 2026 | 20.54 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gilead Sciences, Inc. | 15.99 |
| Regeneron Pharmaceuticals, Inc. | 2.936 |
| AbbVie, Inc. | -- |
| Biogen, Inc. | 1.956 |
| Vertex Pharmaceuticals, Inc. | 6.580 |
Price to Book Value Related Metrics
| PE Ratio | 27.09 |
| PS Ratio | 6.522 |
| PEG Ratio | 0.8137 |
| Price to Free Cash Flow | 26.53 |
| Price | 467.06 |
| Earnings Yield | 3.69% |
| Market Cap | 252.63B |
| PEGY Ratio | 0.7648 |
| Operating PE Ratio | 18.32 |
| Normalized PE Ratio | 24.86 |